AR066171A1 - Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. - Google Patents
Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer.Info
- Publication number
- AR066171A1 AR066171A1 ARP080104193A ARP080104193A AR066171A1 AR 066171 A1 AR066171 A1 AR 066171A1 AR P080104193 A ARP080104193 A AR P080104193A AR P080104193 A ARP080104193 A AR P080104193A AR 066171 A1 AR066171 A1 AR 066171A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- atom
- hydrogen atom
- alkoxy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical class N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- -1 -OH Chemical group 0.000 abstract 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052796 boron Inorganic materials 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Compuesto de formula (1) en la que: A representa un grupo -NR1R'1 o alcoxi C1-6; Z y Z' representan respectivamente N y CH; N y CF; N y N ; CH y CH; CH y N; L representa un grupo -CH=CH- o -CH2CH2- o -(CH2)n-Y- en el que el grupo Y (unido al C=O) representa un átomo de oxigeno o un grupo -NH- y n es un numero entero que va de 1 a 4; R1 y R'1 son tal que: (i) R1 representa: un átomo de hidrogeno; un grupo arilo eventualmente sustituido por uno o varios átomos de halogeno; un grupo heteroarilo; un grupo cicloalquilo C3-6; un grupo alquilo C1-6, eventualmente sustituido por uno o varios grupos hidroxi o alcoxi C1-6, preferentemente alcoxi C1-4; un grupo arilo; un grupo cicloalquilo C3-6; un grupo heteroarilo, un grupo heterocicloalquilo; un grupo -NRaRb en el que Ra y Rb representan independientemente uno de otro un átomo de hidrogeno o un grupo alquilo C1-6, preferentemente alquilo C1-4 o forman junto con el átomo de nitrogeno al que están unidos un grupo heterocicloalquilo que comprende eventualmente otro átomo de nitrogeno y R1' representa un átomo de hidrogeno o un grupo alquilo C1-6 o (ii) R1 y R'1 forman junto con el átomo de nitrogeno al que están unidos un grupo heterocicloalquilo; R2 representa un grupo -Q-R4; Q representa un átomo de oxígeno o el grupo -NH-; R4 representa un átomo de hidrogeno, un grupo heteroarilo, un grupo cicloalquilo C3-6, un grupo alquilo C1-6, eventualmente sustituido por: uno o varios grupos hidroxi o alcoxi C1-6, preferentemente alcoxi C1-4; un grupo heteroarilo, un grupo heterocicloalquilo; un grupo -NRcRd en el que Rc y Rd representan independientemente uno del otro un átomo de hidrogeno o un grupo alquilo C1-6 o forman junto con el átomo de nitrogeno al que están unidos un grupo heterocicloalquilo que comprende eventualmente en el ciclo otro heteroátomo tal como un átomo de nitrogeno, de oxigeno o el grupo -S(O)q con q= 0, 1 o 2 y estando eventualmente sustituido con uno o varios sustituyente(s), idénticos o diferentes los unos de los otros cuando hay varios, elegido(s) entre un átomo de halogeno o un grupo -OH; alcoxi C1-4 o alquilo C1-4; R3 representa al menos un sustituyente del nucleo piridino elegido entre un átomo de hidrogeno o de fluor, un grupo alquilo C1-4, alcoxi C1-4, -OH, -CN o -NReRf en el que Re y Rf representan un átomo de hidrogeno o un grupo alquilo C1-4 o bien Re representa un átomo de hidrogeno y Rf representa un grupo alquilo C1-4, -C(=O)-Oalquilo C1-4 o -C(=O)-alquilo C1-4. Reivindicacion 37: Compuesto de formula (2) en la que L representa un grupo -CH=CH- o -CH2CH2 o -(CH2)n-Y-, en el que el grupo Y (unido al C=O) representa un átomo de oxígeno o un grupo -NH- y n es un numero entero que va de 1 a 4, R3 es tal como se define en la reivindicacion 1, 2 o 27 y K y K' representan un átomo de hidrogeno, un grupo alquilo o arilo, opcionalmente unidos entre ellos para formar juntos con el átomo de boro y los dos átomos de oxigeno un ciclo de 5 a 7 eslabones. Reivindicacion 38: Compuesto segun la reivindicacion 37, caracterizado por que -B(OK)(OK') representa uno de los grupos siguientes de formulas (3).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0706799A FR2921657A1 (fr) | 2007-09-28 | 2007-09-28 | Derives de nicotinamide, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066171A1 true AR066171A1 (es) | 2009-07-29 |
Family
ID=39356668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104193A AR066171A1 (es) | 2007-09-28 | 2008-09-26 | Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100222319A1 (es) |
| EP (1) | EP2205566A2 (es) |
| JP (1) | JP2010540504A (es) |
| KR (1) | KR20100065165A (es) |
| CN (1) | CN101808996A (es) |
| AR (1) | AR066171A1 (es) |
| AU (1) | AU2008334457A1 (es) |
| BR (1) | BRPI0817973A2 (es) |
| CA (1) | CA2700559A1 (es) |
| CL (1) | CL2008002893A1 (es) |
| FR (1) | FR2921657A1 (es) |
| IL (1) | IL204663A0 (es) |
| MX (1) | MX2010003445A (es) |
| PA (1) | PA8797301A1 (es) |
| PE (1) | PE20091033A1 (es) |
| RU (1) | RU2010116765A (es) |
| TW (1) | TW200918056A (es) |
| UY (1) | UY31367A1 (es) |
| WO (1) | WO2009074749A2 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2404919T3 (pl) | 2005-11-08 | 2014-01-31 | Vertex Pharma | Związek heterocykliczny użyteczny jako modulator transporterów zawierających kasetę wiążącą ATP |
| WO2008141119A2 (en) | 2007-05-09 | 2008-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| RS55360B1 (sr) * | 2007-12-07 | 2017-03-31 | Vertex Pharma | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina |
| KR20160040745A (ko) | 2007-12-07 | 2016-04-14 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| FR2943669B1 (fr) * | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
| FR2943670B1 (fr) * | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives anticancereux,leur preparation et leur application en therapeutique |
| FR2943675A1 (fr) * | 2009-03-24 | 2010-10-01 | Sanofi Aventis | Composes anticancereux, leur preparation et leur application en therapeutique |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| CA2791680A1 (en) * | 2010-03-01 | 2011-09-09 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| EP4005559B1 (en) | 2010-04-07 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| US8827372B2 (en) | 2010-07-07 | 2014-09-09 | Frontis Corp. | Blowing system |
| FR2965263A1 (fr) * | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique |
| CN103012397B (zh) * | 2011-09-26 | 2017-03-01 | 赛诺菲 | 吡唑并喹啉酮衍生物、其制备方法及其治疗用途 |
| US9169246B2 (en) | 2011-09-26 | 2015-10-27 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
| PL2573073T3 (pl) * | 2011-09-26 | 2015-04-30 | Sanofi Sa | Pochodne pirazolochinolinonu, ich wytwarzanie i ich zastosowanie terapeutyczne |
| RU2644723C2 (ru) | 2012-01-25 | 2018-02-13 | Вертекс Фармасьютикалз Инкорпорейтед | Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
| RU2016122882A (ru) | 2013-11-12 | 2017-12-19 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
| CN103804270B (zh) * | 2014-01-23 | 2016-06-22 | 中国药科大学 | 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用 |
| HRP20211194T1 (hr) | 2014-11-18 | 2021-10-29 | Vertex Pharmaceuticals Inc. | Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti |
| CN107522641B (zh) * | 2016-06-22 | 2020-05-05 | 复旦大学 | 联芳基脲类衍生物或其盐及其制备方法和用途 |
| JP7092356B2 (ja) | 2016-06-22 | 2022-06-28 | フーダン ユニヴァーシティ | ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用 |
| CN119775198A (zh) * | 2018-05-04 | 2025-04-08 | 治疗方案股份有限公司 | 靶向癌症干细胞的癌症治疗 |
| CN110396065A (zh) * | 2019-06-25 | 2019-11-01 | 南京普锐达医药科技有限公司 | 一种2,4-二氯-5-嘧啶甲酰氯的合成方法 |
| KR20220110744A (ko) * | 2019-11-06 | 2022-08-09 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4301110A1 (de) * | 1993-01-18 | 1994-07-21 | Bayer Ag | Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin |
| HRP20010531A2 (en) * | 1998-12-16 | 2002-08-31 | Bayer Ag | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
| DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| PE20051046A1 (es) * | 2003-11-28 | 2006-01-11 | Novartis Ag | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
-
2007
- 2007-09-28 FR FR0706799A patent/FR2921657A1/fr not_active Withdrawn
-
2008
- 2008-09-24 TW TW097136703A patent/TW200918056A/zh unknown
- 2008-09-26 BR BRPI0817973-5A patent/BRPI0817973A2/pt not_active IP Right Cessation
- 2008-09-26 KR KR1020107006595A patent/KR20100065165A/ko not_active Withdrawn
- 2008-09-26 PA PA20088797301A patent/PA8797301A1/es unknown
- 2008-09-26 EP EP08859496A patent/EP2205566A2/fr not_active Withdrawn
- 2008-09-26 CN CN200880109332A patent/CN101808996A/zh active Pending
- 2008-09-26 AR ARP080104193A patent/AR066171A1/es unknown
- 2008-09-26 UY UY31367A patent/UY31367A1/es not_active Application Discontinuation
- 2008-09-26 RU RU2010116765/04A patent/RU2010116765A/ru not_active Application Discontinuation
- 2008-09-26 MX MX2010003445A patent/MX2010003445A/es not_active Application Discontinuation
- 2008-09-26 WO PCT/FR2008/001338 patent/WO2009074749A2/fr not_active Ceased
- 2008-09-26 JP JP2010526335A patent/JP2010540504A/ja not_active Withdrawn
- 2008-09-26 CL CL2008002893A patent/CL2008002893A1/es unknown
- 2008-09-26 PE PE2008001687A patent/PE20091033A1/es not_active Application Discontinuation
- 2008-09-26 AU AU2008334457A patent/AU2008334457A1/en not_active Abandoned
- 2008-09-26 CA CA2700559A patent/CA2700559A1/fr not_active Abandoned
-
2010
- 2010-03-22 IL IL204663A patent/IL204663A0/en unknown
- 2010-03-26 US US12/732,749 patent/US20100222319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100222319A1 (en) | 2010-09-02 |
| CN101808996A (zh) | 2010-08-18 |
| TW200918056A (en) | 2009-05-01 |
| WO2009074749A2 (fr) | 2009-06-18 |
| EP2205566A2 (fr) | 2010-07-14 |
| UY31367A1 (es) | 2009-04-30 |
| WO2009074749A3 (fr) | 2009-08-20 |
| JP2010540504A (ja) | 2010-12-24 |
| PA8797301A1 (es) | 2009-05-15 |
| RU2010116765A (ru) | 2011-11-27 |
| KR20100065165A (ko) | 2010-06-15 |
| BRPI0817973A2 (pt) | 2019-04-09 |
| PE20091033A1 (es) | 2009-08-17 |
| FR2921657A1 (fr) | 2009-04-03 |
| CA2700559A1 (fr) | 2009-06-18 |
| MX2010003445A (es) | 2010-04-27 |
| AU2008334457A1 (en) | 2009-06-18 |
| IL204663A0 (en) | 2010-11-30 |
| CL2008002893A1 (es) | 2009-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066171A1 (es) | Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. | |
| AR075920A1 (es) | Derivados de nicotinamida su preparacion y su aplicacion en terapeutica | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| AR084220A1 (es) | Acidos 1-bencilcicloalquilcarboxilicos sustituidos, su uso y metodo de preparacion | |
| AR097008A1 (es) | Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| ECSP099269A (es) | Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble | |
| CO6362007A2 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica | |
| AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| AR066524A1 (es) | Azetidinas, composiciones farmaceuticas que las comprenden y uso como antagonistas de ep2 | |
| AR066955A1 (es) | Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica | |
| AR071619A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. | |
| AR082912A1 (es) | Metodo para producir compuestos de piridazinona y un intermediario de sintesis | |
| ES2667276T3 (es) | Derivados de sulfonilindol y método para prepararlos | |
| CO5650235A2 (es) | Derivados de imidazol | |
| UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones | |
| AR098528A1 (es) | Derivados imidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |